BioPharmX Corp. | Income Statement
Fiscal year is February-January. All values USD Thousands.
2013
2014
2016
2017
2018
2019
Sales/Revenue
-
-
64.00
100.00
73.00
57
Cost of Goods Sold (COGS) incl. D&A
0.20
25.00
237.00
516.00
250.00
83
Gross Income
0.20
25.00
173.00
416.00
177.00
26
SG&A Expense
52.10
7,746.00
14,985.00
18,010.00
16,699.00
16,480
EBIT
52.30
7,771.00
15,158.00
18,426.00
16,876.00
16,506
Unusual Expense
-
-
-
90.00
364.00
846
Non Operating Income/Expense
-
40.00
436.00
141.00
126.00
96
Interest Expense
-
76.00
-
-
-
-
Pretax Income
52.30
7,807.00
15,594.00
18,404.00
16,638.00
17,256
Income Tax
-
-
4.00
2.00
2.00
2
Consolidated Net Income
52.30
7,807.00
15,598.00
18,406.00
16,640.00
17,258
Net Income
52.30
7,807.00
15,598.00
18,406.00
16,640.00
17,258
Net Income After Extraordinaries
52.30
7,807.00
15,598.00
18,406.00
16,640.00
17,258
Net Income Available to Common
52.30
8,129.00
16,001.00
18,532.00
16,640.00
17,258
EPS (Basic)
0.01
0.80
0.89
0.52
0.19
2.23
Basic Shares Outstanding
9,000.00
10,217.00
17,950.00
35,806.00
85,900.00
7,727.10
EPS (Diluted)
0.01
0.80
0.89
0.52
0.19
2.23
Diluted Shares Outstanding
9,000.00
10,217.00
17,950.00
35,806.00
85,900.00
7,727.10
EBITDA
52.10
7,746.00
15,072.00
18,239.00
16,824.00
16,444
Non-Operating Interest Income
0.00
-
-
-
-
-
Preferred Dividends
-
322.00
403.00
126.00
-
-
About BioPharmX
View Profile
